Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net loss	$ (51,546)	$ (18,149)
Adjustments to reconcile net loss to cash used in operating activities:
Acquired in-process research and development	23,049
Depreciation and amortization	56	34
Stock-based compensation	2,600	2,108
Net unrealized loss on foreign currency transactions	245	107
Amortization of term loan discount and issuance costs	100	126
Amortization/accretion of investments, net	73	205
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(220)	1,252
Accounts payable	3,623	(971)
Accrued expenses	(1,447)	350
Right-of-use assets and lease liabilities, net	74
Net cash used in operating activities	(23,393)	(14,938)
Investing activities:
Purchases of property and equipment	(277)	(23)
Purchases of short-term investments	(14,962)	(7,605)
Maturities of short-term investments	11,245	41,455
Net cash (used in) provided by investing activities	(3,294)	33,827
Financing activities:
Proceeds from registered direct offering, net of offering costs		29,909
Proceeds from exercises of stock options		626
Proceeds from employee stock purchase plan purchases	141	127
Net cash provided by financing activities	141	30,662
Effect of exchange rate changes on cash and cash equivalents	(12)	(8)
Net (decrease) increase in cash and cash equivalents	(26,558)	49,543
Cash and cash equivalents at beginning of period	50,366	23,982
Cash and cash equivalents at end of period	23,808	73,525
Supplemental cash flow information:
Unsettled stock option exercises		174
Property and equipment in accounts payable		$ 25
Bioniz
Investing activities:
Cash acquired in Bioniz acquisition	700
Supplemental cash flow information:
Fair value of Bioniz assets acquired	23,049
Issuance of common stock for Bioniz acquisition	(22,542)
Bioniz net liabilities assumed	$ 507